ECEESPE2025 Poster Presentations Multisystem Endocrine Disorders (43 abstracts)
1Medscape Education Global, London, United Kingdom; 2HypoPARAthyroidism Association, Aldie, VA, United States; 3HypoPARAthyroidism Association, Frisco, TX, United States; 4McMaster University, Hamilton ON, Canada; 5University Vita-Salute San Raffaele, Milan, Italy; 6University of Virginia School of Medicine, Charlottesville VA, United States; 7HypoPARAthyroidism Association, Spokane Osteoporosis and Endocrinology, Spokane WA, United States; 8Endocrine Research Unit, San Francisco Department of Veterans Affairs Medical Center, University of California, San Francisco, San Francisco, CA, United States
JOINT442
Background: Managing chronic hypoparathyroidism is challenging; but innovative therapies are shifting treatment paradigms from reliance on oral calcium and activated vitamin D analogs to restoring parathyroid hormone (PTH) receptor activation in critical tissues like the kidneys and bones. However, many endocrinologists and nephrologists lack familiarity with these approaches and in evaluating their efficacy. To address these gaps, we developed a series of continuing medical education (CME) activities, to improve physician knowledge across 4 learning needs:.
1. The burden of hypoparathyroidism.
2. Limitations of current therapies.
3. Mechanisms of emerging therapies.
4. Expectations for these emerging therapies.
Methods: Three online video/synchronized slide-based CME activities were launched in May, June, and October 2024each featuring different expert endocrinologists and patients with hypoparathyroidism sharing their diagnosis/management experiences and recent clinical data.1-3 The effects of each activity were assessed using a multi-question, repeated pairs, pre-assessment/post-assessment study design. We analyzed results across all 3 activities in Jan-2025, with questions grouped according to the 4 identified learning needs. Differences pre- and post-assessment were evaluated using McNemars test.
Results: Confidence in understanding the burden of chronic hypoparathyroidism improved for 37% of endocrinologists and 35% of nephrologists, as did implementing best practice guidelines for 40% of endocrinologists and 36% of nephrologists. Significant improvements in knowledge were also observed, particularly regarding the burden of living with hypoparathyroidism. Baseline knowledge of the mechanisms and expectations of emerging therapies was limited, but notable gains were made (Table).
Correct response rates | ||||||
Learning Need | Specialists | n | Pre | Post | δ | P value |
Burden of hypoparathyroidism | Endocrinologists | 281 | 60% | 76% | 16% | P<.001 |
Nephrologists | 133 | 59% | 76% | 17% | P<.001 | |
Limitations of current therapies | Endocrinologists | 420 | 81% | 90% | 9% | P=NS |
Nephrologists | 183 | 68% | 78% | 10% | P<.001 | |
Mechanisms of emerging therapies | Endocrinologists | 341 | 22% | 31% | 9% | P <.001 |
Nephrologists | 124 | 21% | 24% | 3% | P <.001 | |
Expectations of emerging therapies | Endocrinologists | 178 | 9% | 21% | 12% | P <.001 |
Nephrologists | 89 | 12% | 13% | 1% | P <.001 |
Conclusions: This study highlights the effectiveness of online CME in improving chronic hypoparathyroidism knowledge. Further education is needed, particularly on the mechanisms and applications of emerging PTH therapies, to enhance provider confidence and transform patient care.
References: 1. www.medscape.org/viewarticle/1000825.
2. www.medscape.org/viewarticle/1001255.
3. www.medscape.org/viewarticle/1001783.